GlassScriptPhysician profile
Steven D Laviola
NPI 1225034416
$415.98
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.15 · 2020: $177 · 2021: $191 · 2022: $15.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $128.63 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $99.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $71.83 | 2020-2021 | |
| Medtronic Vascular, INC. | $40.07 | 2020 | |
| Bardy Diagnostics, INC. | $29.25 | 2020 | |
| Merck Sharp & Dohme LLC | $17.14 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.13 | 2022 | |
| Esperion Therapeutics, INC. | $14.93 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Laviola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.